Monoclonal antibodies as pharmacokinetic antagonists for the treatment of (+)-methamphetamine addiction

CNS and Neurological Disorders - Drug Targets

Volumn 10, Issue 8, 2011, Pages 892-898

  Owens, S Michael ^a   Atchley, William T ^a   Hambuchen, Michael D ^a   Peterson, Eric C ^a   Gentry, W Brooks ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Addiction; Amphetamines; Monoclonal antibodies; Pharmacokinetics; Rat; Vaccines

Indexed keywords

IMMUNOGLOBULIN G; METHAMPHETAMINE; METHAMPHETAMINE MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; PHENCYCLIDINE; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ADAPTIVE IMMUNITY; ANTIGEN BINDING; AREA UNDER THE CURVE; BINDING AFFINITY; BLOOD BRAIN BARRIER; DRUG BINDING SITE; DRUG CLEARANCE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SELF ADMINISTRATION; HUMAN; LIPID SOLUBILITY; METHAMPHETAMINE ADDICTION; NONHUMAN; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; HUMANS; METHAMPHETAMINE; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 84857773125     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Cook, C.E.; Jeffcoat, A.R.; Hill, J.M.; Pugh, D.E.; Patetta, P.K.; Sadler, B.M.; White, W.R.; Perez-Reyes, M. Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. Drug Metab. Dispos., 1993, 21, 717-723.
2. Kosten, T.; Owens, S.M. Immunotherapy for the treatment of drug abuse. Pharmacol. Ther., 2005, 108, 76-85.
3. Gentry, W.B.; Rüedi-Bettschen, D.; Owens, S.M. Anti-(+)- methamphetamine monoclonal antibody antagonists designed to prevent the progression of human diseases of addiction. Clin. Pharmacol. Ther., 2010, 88, 390-393.
4. Carrera, M.R.; Ashley, J.A.; Parsons, L.H.; Wirsching, P.; Koob, G.F.; Janda, K.D. Suppression of psychoactive effects of cocaine by active immunization. Nature, 1995, 378, 727-730.
5. Fox, B.S.; Kantak, K.M.; Edwards, M.A.; Black, K.M.; Bollinger, B.K.; Botka, A.J.; French, T.L.; Thompson, T.L.; Schad, V.C.; Greenstein, J.L.; Gefter, M.L.; Exley, M.A.; Swain, P.A.; Briner, T.J. Efficacy of a therapeutic cocaine vaccine in rodent models. Nat. Med., 1996, 2, 1129-1132.
6. Laurenzana, E.M.; Gunnell, M.G.; Gentry, W.B.; Owens, S.M. Treatment of adverse effects of excessive phencyclidine exposure in rats with a minimal dose of monoclonal antibody. J. Pharmacol. Exp. Ther., 2003, 306, 1092-1098.
7. Cho, A.; Melega, W. Patterns of methamphetamine abuse and their consequences. J. Addictive Dis., 2001, 21, 21-34.
8. Rawson, R.A.; Condon, T.P. Why do we need an Addiction supplement focused on methamphetamine? Addiction, 2007, 102(Suppl 1), 1-4.
9. Galloway, G.P.; Singleton, E.G.; Buscemi, R.; Baggott, M.J.; Dickerhoof, R.M.; Mendelson, J.E. Methamphetamine Treatment Project Corporate Authors: An examination of drug craving over time in abstinent methamphetamine users. Am. J. Addict., 2010, 19, 510-514.
10. Cho, A.K. Ice: a new dosage form of an old drug. Science, 1990, 249, 631-634.
11. Seiden, L.S.; Sabol, K.E.; Ricaurte, G.A. Amphetamine: effects on catecholamine systems and behavior. Annu. Rev. Pharmacol. Toxicol., 1993, 33, 639-677.
12. Sekine, Y.; Ouchi, Y.; Takei, N.; Yoshikawa, E.; Nakamura, K.; Futatsubashi, M.; Okada, H.; Minabe, Y.; Suzuki, K.; Iwata, Y.; Tsuchiya, K.J.; Tsukada, H.; Iyo, M.; Mori, N. Brain serotonin transporter density and aggression in abstinent methamphetamine abusers. Arch. Gen. Psychiatry, 2006, 63, 90-100.
13. McCann, U.D.; Wong, D.F.; Yokoi, F.; Villemagne, V.; Dannals, R.F.; Ricaurte, G.A. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J. Neurosci., 1998, 18, 8417-8422.
14. Ernst, T.; Chang, L.; Leonido-Yee, M.; Speck, O. Evidence for long-term neurotoxicity associated with methamphetamine abuse: A 1H MRS study. Neurology, 2000, 54, 1344-1349.
15. Volkow, N.D.; Chang, L.; Wang, G.J.; Fowler, J.S.; Franceschi, D.; Sedler, M.; Gatley, S.J.; Miller, E.; Hitzemann, R.; Ding, Y.S.; Logan, J. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J. Neurosci., 2001, 21, 9414-9418.
16. Rivière, G.J.; Gentry, W.B.; Owens, S.M. Disposition of methamphetamine and its metabolite amphetamine in brain and other tissues in rats after intravenous administration. J. Pharmacol. Exp. Ther., 2000, 292, 1042-1047.
17. Russell, M.A.; Feyerabend, C. Cigarette smoking: a dependence on high-nicotine boli. Drug Metab. Rev., 1978, 8, 29-57.
18. Proksch, J.W.; Gentry, W.B.; Owens, S.M. The effect of rate of drug administration on the extent and time course of phencyclidine distribution in rat brain, testis, and serum. Drug Metab. Dispos., 2000, 28, 742-747.
19. Pitas, G.; Laurenzana, E.M.; Williams, D.K.; Owens, S.M.; Gentry, W.B. Anti-phencyclidine monoclonal antibody binding capacity is not the only determinant of effectiveness, disproving the concept that antibody capacity is easily surmounted. Drug Metab. Dispos., 2006, 34, 906-912.
20. Brambell, F.; Hemmings, W. A theoretical model of gammaglobulin catabolism. Nature, 1964, 203, 1352-1354.
21. Lobo, E.D.; Hansen, R.J.; Balthasar, J.P. Antibody pharmacokinetics and pharmacodynamics. J. Pharm. Sci., 2004, 93, 2645-2668.
22. Hubbard, J.J.; Laurenzana, E.M.; Williams, D.K.; Gentry, W.B.; Owens, S.M. The fate and function of therapeutic antiaddiction monoclonal antibodies across the reproductive cycle of rats. J. Pharmacol. Exp. Ther., 2011, 336, 414-422.
23. Lu, W.; Zhao, Z.; Zhao, Y.; Yu, S.; Zhao, Y.; Fan, B.; Kacskovics, I.; Hammarström, L.; Li, N. Over-expression of the bovine FcRn in the mammary gland results in increased IgG levels in both milk and serum of transgenic mice. Immunology, 2007, 122, 401-408.
24. Roopenian, D.C.; Akilesh, S. FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol., 2007, 7, 715-725.
25. Arizono, H.; Ishii, S.; Nagao, T.; Kudo, S.; Sasaki, S.; Kondo, S.; Kiyoki, M. Pharmacokinetics of a new human monoclonal antibody against cytomegalovirus. First communication: plasma concentration, distribution, metabolism and excretion of the new monoclonal antibody, regavirumab after intravenous administration in rats and rabbits. Arzneimittelforschung, 1994, 44, 890-898.
26. Bichler, J.; Schöndorfer, G.; Pabst, G.; Andresen, I. Pharmacokinetics of anti-D IgG in pregnant RhD-negative women. BJOG, 2003, 110, 39-45.
27. Anglin, M.D.; Burke, C.; Perrochet, B.; Stamper, E.; Dawud- Noursi, S. History of the methamphetamine problem. J. Psychoactive Drugs, 2000, 32, 137-141.
28. Cohen, J.B.; Greenberg, R.; Uri, J.; Halpin, M.; Zweben, J.E. Women with methamphetamine dependence: research on etiology and treatment. J. Psychoactive Drugs, 2007, Suppl 4, 347-351.
29. Zhang, Y.; Pardridge, W.M. Mediated efflux of IgG molecules from brain to blood across the blood-brain barrier. J. Neuroimmunol., 2001, 114, 168-172.
30. Proksch, J.W.; Gentry, W.B.; Owens, S.M. Anti-phencyclidine monoclonal antibodies provide long-term reductions in brain phencyclidine concentrations during chronic phencyclidine administration in rats. J. Pharmacol. Exp. Ther., 2000, 292, 831-837.
31. Laurenzana, E.M.; Byrnes-Blake, K.A.; Milesi-Hallé, A.; Gentry, W.B.; Williams, D.K.; Owens, S.M. Use of anti-(+)- methamphetamine monoclonal antibody to significantly alter (+)- methamphetamine and (+)-amphetamine disposition in rats. Drug Metab. Dispos., 2003, 31, 1320-1326.
32. Valentine, J.L.; Owens, S.M. Antiphencyclidine monoclonal antibody therapy significantly changes phencyclidine concentrations in brain and other tissues in rats. J. Pharmacol. Exp. Ther., 1996, 278, 717-724.
33. McClurkan, M.B.; Valentine, J.L.; Arnold, L.; Owens, S.M. Disposition of a monoclonal anti-phencyclidine Fab fragment of immunoglobulin G in rats. J. Pharmacol. Exp. Ther., 1993, 266, 1439-1445.
34. Hardin, J.S.; Wessinger, W.D.; Wenger, G.R.; Proksch, J.W.; Laurenzana, E.M.; Owens, S.M. A single dose of monoclonal antiphencyclidine IgG offers long-term reductions in phencyclidine behavioral effects in rats. J. Pharmacol. Exp. Ther., 2002, 302, 119-126.
35. Byrnes-Blake, K.A.; Laurenzana, E.M.; Landes, R.D.; Gentry, W.B.; Owens, S.M. Monoclonal IgG affinity and treatment time alters antagonism of (+)-methamphetamine effects in rats. Eur. J. Pharmacol., 2005, 521, 86-94.
36. Laurenzana, E.; Hendrickson, H.; Carpenter, D. Functional and biological determinants affecting the duration of action and efficacy of anti-(+)-methamphetamine monoclonal antibodies in rats. Vaccine, 2009, 27(50), 7011-7020.
37. Peterson, E.C.; Gunnell, M.; Che, Y.; Goforth, R.L.; Carroll, F.I.; Henry, R.; Liu, H.; Owens, S.M. Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse. J. Pharmacol. Exp. Ther., 2007, 322, 30-39.
38. Bazin-Redureau, M.I.; Renard, C.B.; Scherrmann, J.M. Pharmacokinetics of heterologous and homologous immunoglobulin G, F(ab')2 and Fab after intravenous administration in the rat. J. Pharm. Pharmacol., 1997, 49, 277-281.
39. Montaño, R.F.; Morrison, S.L. Influence of the isotype of the light chain on the properties of IgG. J. Immunol., 2002, 168, 224-231.
40. Roskos, L.K.; Davis, C.G.; Schwab, G.M. The clinical pharmacology of therapeutic monoclonal antibodies. Drug Dev. Res., 2004, 61, 108-120.
41. Carroll, F.I.; Abraham, P.; Gong, P.K.; Pidaparthi, R.R.; Blough, B.E.; Che, Y.; Hampton, A.; Gunnell, M.; Lay, J.O.; Peterson, E.C.; Owens, S.M. The synthesis of haptens and their use for the development of monoclonal antibodies for treating methamphetamine abuse. J. Med. Chem., 2009, 52, 7301-7309.
42. McMillan, D.E.; Hardwick, W.C.; Li, M.; Gunnell, M.G.; Carroll, F.I.; Abraham, P.; Owens, S.M. Effects of murine-derived antimethamphetamine monoclonal antibodies on (+)-methamphetamine self-administration in the rat. J. Pharmacol. Exp. Ther., 2004, 309, 1248-1255.
43. Jiang, X.-R.; Song, A.; Bergelson, S.; Arroll, T.; Parekh, B.; May, K.; Chung, S.; Strouse, R.; Mire-Sluis, A.; Schenerman, M. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat. Rev. Drug Discov., 2011, 10, 101-111.
44. Rivière, G.J.; Byrnes, K.A.; Gentry, W.B.; Owens, S.M. Spontaneous locomotor activity and pharmacokinetics of intravenous methamphetamine and its metabolite amphetamine in the rat. J. Pharmacol. Exp. Ther., 1999, 291, 1220-1226.
45. Hendrickson, H.; Laurenzana, E.; Owens, S.M. Quantitative determination of total methamphetamine and active metabolites in rat tissue by liquid chromatography with tandem mass spectrometric detection. AAPS J., 2006, 8, E709-E717.